SCHEMBL10245320

SCHEMBL10245320

CCN(CCNC(=O)OC)C(C)c1ccc(OC)c(CC#N)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.36
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CYP1A2 P05177 1/20 0.34
LMNA P02545 2/20 0.34
TSHR P16473 2/20 0.34
ADRA2A P08913 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
HTR2B P41595 1/20 0.34
STAT6 P42226 1/20 0.34
KCNH2 Q12809 1/20 0.34
MCHR1 Q99705 1/20 0.34
REN P00797 2/20 0.34
BLM P54132 1/20 0.33
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243935 0.86 PKM (0.45) S1PR1TMEM97SIGMAR1LMNATSHR
SCHEMBL10282516 0.86 S1PR1 (0.37) S1PR1TMEM97SIGMAR1CYP1A2LMNA
SCHEMBL336196 0.82 CYP1A2 (0.36) S1PR1CYP1A2
SCHEMBL10243957 0.81 L3MBTL1 (0.46) S1PR1TSHRALDH1A1
SCHEMBL10244047 0.81 L3MBTL1 (0.47) S1PR1TSHRALDH1A1
SCHEMBL10243900 0.79 S1PR1 (0.44) S1PR1LMNACYP2D6CYP2C9ALDH1A1
SCHEMBL10243744 0.77 POLB (0.41) ALDH1A1
SCHEMBL10244037 0.77 CYP1A2 (0.46) CYP1A2CYP2D6ALDH1A1
SCHEMBL10244482 0.76 POLB (0.45) CYP1A2LMNATSHRALDH1A1
SCHEMBL10244300 0.76 MTNR1A (0.48) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 S1PR1 1754/4885TMEM97 4545/4885SIGMAR1 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.